NeuroSense Therapeutics Ltd. Private Placement Deal
Ticker: NRSNW · Form: 6-K · Filed: Dec 2, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Dec 2, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $1, $1.2499, $5.0 m, $1.25, $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: private-placement, securities-purchase-agreement, capital-raise
Related Tickers: NRSN
TL;DR
NeuroSense Therapeutics inks private placement deal with investor and CEO.
AI Summary
On December 2, 2024, NeuroSense Therapeutics Ltd. entered into a Securities Purchase Agreement with a single investor and its CEO, Alon Ben-Noon. The agreement details the issuance and sale of securities in a private placement directly to the investor.
Why It Matters
This private placement indicates a capital raise activity for NeuroSense Therapeutics, potentially funding ongoing research and development for its pharmaceutical products.
Risk Assessment
Risk Level: medium — Private placements can sometimes signal a need for capital and may involve less stringent disclosure requirements than public offerings.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the 6-K report and party to the agreement.
- Alon Ben-Noon (person) — CEO of NeuroSense Therapeutics and a purchaser in the agreement.
- Securities Purchase Agreement (document) — The agreement entered into on December 2, 2024.
- December 2, 2024 (date) — Date of the Securities Purchase Agreement.
FAQ
What specific securities were sold in the private placement?
The filing states that the Company agreed to issue and sell securities, but does not specify the type of securities in this excerpt.
What is the total dollar amount of the private placement?
The provided text does not disclose the total dollar amount of the private placement.
Who is the single investor involved in the Securities Purchase Agreement?
The filing refers to 'a single investor' but does not name the specific entity in this excerpt.
What is the purpose of this private placement for NeuroSense Therapeutics Ltd.?
The filing does not explicitly state the purpose of the private placement, but such actions are typically for capital raising.
Is Alon Ben-Noon purchasing securities as an individual or on behalf of another entity?
The filing states Alon Ben-Noon is the Company's Chief Executive Officer and is a Purchaser, implying he is acting in a personal capacity or as part of the defined 'Purchasers' group.
Filing Stats: 1,500 words · 6 min read · ~5 pages · Grade level 16.5 · Accepted 2024-12-02 16:15:42
Key Financial Figures
- $1 — and accompanying Ordinary Warrants was $1.25, and the purchase price of each Pre-
- $1.2499 — and accompanying Ordinary Warrants was $1.2499. The gross proceeds to the Company from
- $5.0 m — fering are expected to be approximately $5.0 million, before deducting offering expens
- $1.25 — y upon issuance at an exercise price of $1.25 per share and expire five years from th
- $0.0001 — y upon issuance at an exercise price of $0.0001 per share and may be exercised at any t
- $2.8 million — re December 5, 2024 against payment for $2.8 million with the remaining proceeds to be paid
- $5 Million — ldquo;NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market
Filing Documents
- ea0223340-6k_neurosense.htm (6-K) — 23KB
- ea022334001ex10-1_neurosense.htm (EX-10.1) — 169KB
- ea022334001ex10-2_neurosense.htm (EX-10.2) — 87KB
- ea022334001ex10-3_neurosense.htm (EX-10.3) — 86KB
- ea022334001ex99-1_neurosense.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-104568.txt ( ) — 382KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: December 2, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 4